Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 1;592(3):491-504.
doi: 10.1113/jphysiol.2013.267294. Epub 2013 Nov 25.

Purinergic control of vascular tone in the retina

Affiliations

Purinergic control of vascular tone in the retina

Joanna Kur et al. J Physiol. .

Abstract

Purinergic control of vascular tone in the CNS has been largely unexplored. This study examines the contribution of endogenous extracellular ATP, acting on vascular smooth muscle cells, in controlling vascular tone in the in vivo rat retina. Retinal vessels were labelled by i.v. injection of a fluorescent dye and imaged with scanning laser confocal microscopy. The diameters of primary arterioles were monitored under control conditions and following intravitreal injection of pharmacological agents. Apyrase (500 units ml(-1)), an ATP hydrolysing enzyme, dilated retinal arterioles by 40.4 ± 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellular ATP levels, constricted arterioles by 58.0 ± 3.8% (P < 0.001 for both), demonstrating the importance of ATP in the control of basal vascular tone. Suramin (500 μm), a broad-spectrum P2 receptor antagonist, dilated retinal arterioles by 50.9 ± 3.7% (P < 0.001). IsoPPADS (300 μm) and TNP-ATP (50 μm), more selective P2X antagonists, dilated arterioles by 41.0 ± 5.3% and 55.2 ± 6.1% respectively (P < 0.001 for both). NF023 (50 μm), a potent antagonist of P2X1 receptors, dilated retinal arterioles by 32.1 ± 2.6% (P < 0.001). A438079 (500 μm) and AZ10606120 (50 μm), P2X7 antagonists, had no effect on basal vascular tone (P = 0.99 and P = 1.00 respectively). In the ex vivo retina, the P2X1 receptor agonist α,β-methylene ATP (300 nm) evoked sustained vasoconstrictions of 18.7 ± 3.2% (P < 0.05). In vivo vitreal injection of the gliotoxin fluorocitrate (150 μm) dilated retinal vessels by 52.3 ± 1.1% (P < 0.001) and inhibited the vasodilatory response to NF023 (50 μm, 7.9 ± 2.0%; P < 0.01). These findings suggest that vascular tone in rat retinal arterioles is maintained by tonic release of ATP from the retina. ATP acts on P2X1 receptors, although contributions from other P2X and P2Y receptors cannot be ruled out. Retinal glial cells are a possible source of the vasoconstricting ATP.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A, in vivo rat preparation. The retina is imaged through an upright microscope and a contact lens placed over the cornea. A hypodermic needle is advanced through the sclera into the vitreous humour and serves as a guard needle for the injection needle. B, low-magnification confocal image of the retinal surface showing arterioles (a) and venules (v) filled with a fluorescent dye and the injection needle positioned over an arteriole. C, high-magnification images of the boxed region in B showing the arteriole before, during and after injection of ATPγS. The dashed line indicates the position at which the vessel diameter was measured. D, line scan image showing the change in diameter of the arteriole as a function of time. The vertical lines indicate the times at which the images in (C) were captured. E, arteriole diameter as a function of time following intravitreal injection of ATPγS (10 μm). The time axes in D and E are aligned.
Figure 2
Figure 2
A, vitreal injection of apyrase (500 units ml−1), an ATP hydrolysing enzyme that reduces endogenous ATP levels, dilated vessels while AOPCP (12.5 mm), an ecto-5′-nucleotidase inhibitor which increases ATP levels, constricted vessels. B, injection of ATPγS (10 μm), a slowly hydrolysable ATP analogue, evoked a large transient vasoconstriction followed by a small, sustained vasodilatation. C, suramin (500 μm), a non-selective P2 receptor antagonist; isoPPADS (300 μm), a P2X receptor antagonist; TNP-ATP (50 μm), a P2X1, P2X3 and P2X2/3 receptor antagonist; and NF023 (50 μm), a P2X1 receptor antagonist, all evoked dilatations of retinal arterioles. A438079 (500 μm) and AZ10606120 (50 μm), P2X7 receptor antagonists, had no effect on arteriole diameter. Vehicle injections (3 μl and 10 μl saline) evoked small, transient vasodilatations. Saline injection volumes in A and B matched the volumes of injected drugs in the respective trials. Traces in A differ in appearance from B and C due to different rates of data collection. Arrows indicate time of vitreal injections. D, summary of in vivo data showing arteriole diameter changes evoked by altered ATP levels and by vitreal injection of P2X receptor antagonists. Vessel diameters were measured after they reached plateau values. Numbers in parentheses indicate number of rats; error bars denote ± s.e.m.; ***P < 0.001 relative to vehicle control. A430879, 3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine; AOPCP, α,β-methylene ADP; AZ10606120, N-[2-[[2-[(2-hydroxyethyl)amino]eth­yl]amino]-5-quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide dihydrochloride; isoPPADS, pyridoxalphosphate-6-azophenyl-2′,5′­disulphonic acid; NF023, 8,8′-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic; TNP-ATP, 2′,3′-O-(2,4,6-trinitrophenyl)-ATP.
Figure 3
Figure 3
A and B, superfusate application of 300 nm and 3 μm α,β-meATP, a selective P2X1 receptor agonist, evoked both transient and sustained vasoconstriction. C, pretreatment with the P2X1 antagonist NF023 (10 μm) abolished vascular responses to α,β-meATP (300 nm). Bars represent application intervals. D, summary data for 300 nm α,β-meATP applied alone (peak and sustained) and after pretreatment with NF023 (10 μm). Note that in contrast to in vivo experiments, NF023 applied ex vivo did not produce dilatation because vessels in the isolated retina lack tone. Numbers in parentheses represent number of retinal preparations (minimum of three animals). *P < 0.05, ***P < 0.001, relative to baseline. α,β-meATP, α,β-methylene ATP; NF023, 8,8′-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic.
Figure 4
Figure 4
A, superfusate application of 10 μm, 100 μm and 1 mm ATP evoked transient and sustained vasoconstriction. Dashed line represents onset of ATP application. B, filled squares: summary data for six retinal preparations from four animals showing the arteriole response to increasing concentrations of ATP (measured at the end of agonist application, 100 s; *P < 0.05, ***P < 0.001, relative to baseline). Open circles: pretreatment with the gliotoxin fluorocitrate (150 μm, 45 min) did not affect the ATP-evoked constrictions of retinal arterioles (n = 6 retinal preparations from three animals, not significant for comparison between ATP alone and after pretreatment with fluorocitrate).
Figure 5
Figure 5
A, intravitreal injection of the gliotoxin fluorocitrate (150 μm) dilated retinal arterioles. Vehicle alone had no effect on arteriole diameter. B, summary data showing the change in arteriole diameter in response to vehicle and fluorocitrate measured 45 min after injection. Numbers in parentheses indicate number of rats. ***P < 0.001, relative to vehicle control.
Figure 6
Figure 6
A, changes in arteriole diameter following sequential intravitreal injections of the gliotoxin FC (150 μm), Et-1 (7–12 nm), a vasoconstricting peptide, and NF023 (50 μm), a P2X1 receptor antagonist. Et-1 restored the tone of the vessel, which was decreased following FC treatment. NF023 injection evoked a small dilatation. B, summary data showing arteriole diameter changes evoked by application of NF023 without pretreatment (data from Fig. 2) and following pretreatment with FC and Et-1. Numbers in parentheses indicate number of rats. **P < 0.01 relative to NF023 alone. Et-1, endothelin-1; FC, fluorocitrate; NF023, 8,8′-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic.

Similar articles

Cited by

References

    1. Akata T. General anaesthetics and vascular smooth muscle: direct actions of general anaesthetics on cellular mechanisms regulating vascular tone. Anesthesiology. 2007;106:365–391. - PubMed
    1. Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature. 2010;468:232–243. - PMC - PubMed
    1. Bekar LK, Wei HS, Nedergaard M. The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J Cereb Blood Flow Metab. 2012;32:2135–2145. - PMC - PubMed
    1. Berkowitz BA, Lukaszew RA, Mullins CM, Penn JS. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1998;39:391–396. - PubMed
    1. Berstad J. The initial phase of the dextran-induced anaphylactoid reaction in the rat: a comparison of inhibitors of the blood pressure fall. Acta Pharmacol Toxicol (Copenh) 1982;51:141–146. - PubMed

Publication types

Substances

LinkOut - more resources